



Date:- February 14, 2013

To,  
The Chief Manager,  
Listing Department  
National Stock Exchange Limited  
C/1, Block G, 5<sup>th</sup> Floor, Exchange Plaza,  
Bandra Kurla Complex, Bandra (E),  
Mumbai - 400 051.

Kind Attn: Mr. Rajesh Modani

Ref.: M/s Sharon Bio-Medicine Ltd., Scrip Code No. SHARONBIO.

Sub: Outcome of Board Meeting held on 14/02/2013

Dear Sir,


Please find the outcome of Board Meeting of the company held on 14/02/2013 at its corporate office at Sharon House, Plot No. 163, Park Street, S.V.P. Nagar, Andheri (W), Mumbai - 400 053.

1. In compliance of clause 41 of Listing Agreement, we hereby attach unaudited financial results for the quarter ended December 31, 2012.
2. Copy of Auditors Limited Review Report for the Quarter ended 31<sup>st</sup> December, 2012.

This is for your information and records.

Thanking you,

Yours faithfully,  
For Sharon Bio-Medicine Limited

  
M. P. Kala  
Director

Regd. Off. & Works I : W-34 & 34/1, MIDC, Talaja, Dist-Raigad, Maharashtra (India),

Works II: Plot No. L-6, MIDC, Talaja, Dist Raigad, Maharashtra (India)

Admin Office : 312, C Wing, BSEL Tech Park, Sector - 30(A), Vashi, Navi Mumbai - 400 705.

Tel.: 91 22 - 67944000, Fax : 91 22 - 67944001

Head Office : Plot No. 163, Smt Janakidevi Public School Rd., SVP Nagar, Andheri (West), Mumbai - 400 053.

Tel. : 91 22 26323192 / 93 / 94 Fax : 26323140 E-mail : info@sharonbio.com

www.sharonbio.com

*Caring for relationships*



**UNAUDITED STANDALONE FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER  
ENDED DECEMBER 31, 2012.**

| SR. NO. | PARTICULARS                                                                                              | Quarter Ended |            |            | Six Months Ended |            | Year Ended           |
|---------|----------------------------------------------------------------------------------------------------------|---------------|------------|------------|------------------|------------|----------------------|
|         |                                                                                                          | 31/12/2012    | 30/09/2012 | 31/12/2011 | 31/12/2012       | 31/12/2011 | 30/06/2012 (Audited) |
|         |                                                                                                          |               |            |            |                  |            | (Rs. In Lacs)        |
| 1       | Net Sales / Income from Operations                                                                       | 24,884.19     | 21,668.14  | 19,684.62  | 46,552.33        | 37,121.11  | 78,506.14            |
|         | Total Income                                                                                             | 24,884.19     | 21,668.14  | 19,684.62  | 46,552.33        | 37,121.11  | 78,506.14            |
| 2       | <b>Total Expenditure</b>                                                                                 |               |            |            |                  |            |                      |
|         | a) Increase/(Decrease) in Stock in Trade                                                                 | (1,045.61)    | (895.70)   | (810.71)   | (1,941.31)       | (1,603.34) | (4,100.20)           |
|         | b) Consumption of Materials                                                                              | 16,994.82     | 14,978.86  | 13,123.11  | 31,973.68        | 25,458.77  | 54,143.31            |
|         | c) Purchases of Trading Goods                                                                            | 5,052.92      | 4,038.52   | 4,200.95   | 9,091.44         | 7,091.30   | 15,554.26            |
|         | d) Employees Cost                                                                                        | 435.74        | 405.35     | 369.11     | 841.09           | 732.00     | 1,397.22             |
|         | e) Depreciation                                                                                          | 280.39        | 226.11     | 241.89     | 506.50           | 488.81     | 886.38               |
|         | f) Other Expenditure                                                                                     | 515.90        | 502.39     | 438.66     | 1,018.29         | 857.44     | 1,983.75             |
|         | Total                                                                                                    | 22,234.16     | 19,255.53  | 17,563.01  | 41,489.69        | 33,024.98  | 69,864.72            |
| 3       | Profit from Operations before Exchange Rate Difference, Other Income, Interest & Exceptional Items (1-2) | 2,650.03      | 2,412.61   | 2,121.61   | 5,062.64         | 4,096.13   | 8,641.42             |
| 4       | Other Income                                                                                             | 25.30         | 20.42      | 20.12      | 45.72            | 38.72      | 92.69                |
| 5       | Profit from Operations before Interest & Exceptional Items (3+4)                                         | 2,675.33      | 2,433.03   | 2,141.73   | 5,108.36         | 4,134.85   | 8,734.11             |
| 6       | Interest                                                                                                 | 1,078.52      | 980.25     | 865.90     | 2,058.77         | 1,687.42   | 3,425.97             |
| 7       | Profit after Interest but before Exception items (5-6)                                                   | 1,596.81      | 1,452.78   | 1,275.83   | 3,049.59         | 2,447.43   | 5,308.14             |
| 8       | Exception Items                                                                                          | -             | -          | -          | -                | -          | 3.14                 |
| 9       | Profit(+)/Loss(-) from Ordinary Activities before tax (7-8)                                              | 1,596.81      | 1,452.78   | 1,275.83   | 3,049.59         | 2,447.43   | 5,305.00             |
| 10      | Tax Expenses                                                                                             | 277.80        | 255.30     | 293.03     | 533.10           | 495.84     | 1,143.56             |
| 11      | Net Profit before ordinary activities (8-9)                                                              | 1,319.01      | 1,197.48   | 982.80     | 2,516.49         | 1,951.59   | 4,161.44             |
| 12      | Extra Ordinary Items (Net of Tax)                                                                        | -             | -          | -          | -                | -          | -                    |
| 13      | Net Profit after Taxes (10-11)                                                                           | 1,319.01      | 1,197.48   | 982.80     | 2,516.49         | 1,951.59   | 4,161.44             |
| 14      | Paid up Equity Share Capital (Face value of Rs.10/- each)                                                | 1,055.69      | 1,055.69   | 1,055.69   | 1,055.69         | 1,055.69   | 1,055.69             |
| 15      | Reserves excluding Revaluation Reserves                                                                  | -             | -          | -          | -                | -          | 17,540.59            |
| 16      | <b>Earning Per Shares</b>                                                                                |               |            |            |                  |            |                      |
|         | i) before extra ordinary items                                                                           | 12.49         | 11.34      | 9.31       | 23.83            | 18.49      | 40.18                |
|         | ii) after extra ordinary items                                                                           | 12.14         | 11.09      | 9.12       | 23.23            | 18.14      | 39.41                |
| 17      | Aggregate of Public Shareholdings                                                                        | 4,194,125     | 4,194,125  | 4,144,325  | 4,194,125        | 4,144,325  | 4,144,325            |
|         | No. of Shares                                                                                            | 39.73%        | 39.73%     | 39.26%     | 39.73%           | 39.26%     | 39.26%               |
|         | Percentage of Shareholdings                                                                              |               |            |            |                  |            |                      |
| 18      | Promoters & promoter group Shareholding                                                                  |               |            |            |                  |            |                      |
|         | a) Pledged / Encumbered                                                                                  |               |            |            |                  |            |                      |
|         | - Number of Shares                                                                                       | 744,500       | 744,500    | 1,300,800  | 744,500          | 1,300,800  | 1,145,360            |
|         | - Percentage of Shares                                                                                   | 11.70%        | 11.70%     | 20.29%     | 11.70%           | 20.29%     | 16.71%               |
|         | (as a % of the total shareholding of promoter & promoter group)                                          | 7.05%         | 7.05%      | 12.32%     | 7.05%            | 12.32%     | 10.85%               |
|         | - Percentage of Shares                                                                                   |               |            |            |                  |            |                      |
|         | (as a % of the total share capital of the Company)                                                       |               |            |            |                  |            |                      |
|         | b) Non-encumbered                                                                                        |               |            |            |                  |            |                      |
|         | - Number of Shares                                                                                       | 5,618,275     | 5,618,275  | 5,111,775  | 5,618,275        | 5,111,775  | 5,267,215            |
|         | - Percentage of Shares                                                                                   | 88.30%        | 88.30%     | 79.71%     | 88.30%           | 79.71%     | 82.14%               |
|         | (as a % of the total shareholding of promoter & promoter group)                                          | 53.22%        | 53.22%     | 48.42%     | 53.22%           | 48.42%     | 49.89%               |
|         | - Percentage of Shares                                                                                   |               |            |            |                  |            |                      |
|         | (as a % of the total share capital of the Company)                                                       |               |            |            |                  |            |                      |

Regd. Off. & Works I : W-34 & 34/1, MIDC, Talaja, Dist-Raigad, Maharashtra (India).

Works II: Plot No. L-6, MIDC, Talaja, Dist Raigad, Maharashtra (India)

Admin Office : 312, C Wing, BSEL Tech Park, Sector - 30(A), Vashi, Navi Mumbai - 400 705.

Tel.: 91 22 - 67944000, Fax : 91 22 - 67944001

Head Office : Plot No. 163, Smt Janakidevi Public School Rd., SVP Nagar, Andheri (West), Mumbai - 400 053.

Tel. : 91 22 26323192 / 93 / 94 Fax : 26323140 E-mail : info@sharonbio.com

www.sharonbio.com

*Caring for relationships*

**NOTES :-**

1. Unaudited Standalone Statement of Assets and Liabilities as at 31st December, 2012  
(Rs. in Lacs)

| Particulars                                     | Six months ended 31/12/2012 | Six months ended 31/12/2011 |
|-------------------------------------------------|-----------------------------|-----------------------------|
| <b>Shareholders' funds</b>                      |                             |                             |
| (a) Capital                                     | 1,055.69                    | 1,055.69                    |
| (b) Reserves and Surplus                        | 22,507.86                   | 21,876.07                   |
| <b>Loan Funds</b>                               | 49,431.81                   | 38,508.45                   |
| <b>Deferred tax liabilities (net)</b>           | 699.27                      | 465.72                      |
| <b>Total</b>                                    | <b>73,694.63</b>            | <b>61,905.93</b>            |
| <b>Fixed Assets</b>                             | 29,634.94                   | 21,896.17                   |
| <b>Investments</b>                              | 398.24                      | 388.24                      |
| <b>Current assets, loans and advances</b>       |                             |                             |
| (a) Inventories                                 | 20,486.00                   | 17,635.83                   |
| (b) Sundry debtors                              | 27,473.56                   | 24,712.36                   |
| (c) Cash and bank balance                       | 605.98                      | 385.49                      |
| (d) Loans and advances                          | 1,217.40                    | 1,021.50                    |
|                                                 | 49,782.94                   | 43,755.18                   |
| <b>Less: Current Liabilities and Provisions</b> |                             |                             |
| (a) Liabilities                                 | 5,096.32                    | 3,218.64                    |
| (b) Provisions                                  | 1,025.17                    | 915.02                      |
|                                                 | 6,121.49                    | 4,133.66                    |
| <b>Net Current Assets</b>                       | 43,661.45                   | 39,621.52                   |
| <b>Total</b>                                    | <b>73,694.63</b>            | <b>61,905.93</b>            |

- 1) The above results for the quarter ended December 31, 2012 have been reviewed by the Audit Committee and were taken on record by the Board of Directors in its meeting held on February 14, 2012.
- 2) The "Limited Review" required under clause 41 of listing agreement has been done by statutory auditors of the Company.
- 3) The Company has provided for Foreign Exchange (Loss)/Gains under Exception Items due to exchange differences arising during the period(s) on foreign currency contracts and borrowings including Foreign Currency Convertible Bonds.
- 4) Previous years figures have been regrouped and recast wherever necessary.
- 5) Information on investor complaints for the quarter ended December 31, 2012 (in nos.)

| Opening Balance of Complaints | Received during the Quarter | Disposed off during Quarter | Closing Balance |
|-------------------------------|-----------------------------|-----------------------------|-----------------|
| NIL                           | 0                           | 0                           | NIL             |

For Sharon Bio-Medicine Ltd.

*Savita*  
Savita Gowda  
Managing Director.

Place : Mumbai.  
Date : 14.02.2013

Regd. Off. & Works I : W-34 & 34/1, MIDC, Talaja, Dist-Raigad, Maharashtra (India),  
Works II: Plot No. L-6, MIDC, Talaja, Dist Raigad, Maharashtra (India)  
Admin Office : 312, C Wing, BSEL Tech Park, Sector - 30(A), Vashi, Navi Mumbai - 400 705.  
Tel.: 91 22 - 67944000, Fax : 91 22 - 67944001  
Head Office : Plot No. 163, Smt Janakidevi Public School Rd., SVP Nagar, Andheri (West), Mumbai - 400 053.  
Tel. : 91 22 26323192 / 93 / 94 Fax : 26323140 E-mail : info@sharonbio.com  
www.sharonbio.com

*Caring for relationships*

**CA. S. C. Agrawal**

B. Com., (Hons.) LL.B., F.C.A., DISA (ICAI)

**Shyam C. Agrawal & Co.****Chartered Accountants**3/63, Nityanand Nagar, Vibhag IV,  
Sahar Road, Andheri (East),  
Mumbai - 400 069.

Tel. : (O) 2684 0916 • Tele Fax : 2683 5699

E-mail : shyam31774@yahoo.com

**REVIEW REPORT**

We have reviewed the accompanying statement of unaudited financial results of **M/s. Sharon Bio-Medicine Ltd.**, for the period ended on **31st December, 2012** except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards<sup>1</sup> and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Shyam C. Agrawal & Co.  
Chartered Accountants



Shyam Agrawal  
Proprietor

Date: 14/02/2013

Place: Mumbai.